ALS occurrence is spontaneous and is characterized by a progressive degeneration of motor nerve cells which control voluntary muscles in the brain (upper motor neurons) and spinal cord (lower motor neurons). ALS is commonly known as Lou Gehrig’s disease. The motor neurons can no longer send impulses to the muscles, which lead to muscles atrophy and increased muscle weakness. ALS can affect anyone worldwide with no ethnic, racial or socioeconomic boundaries. In general, most patients are being diagnosed at ages of between 40 and 70, with the average of being 55 years old. The number of patients who have been affected by ALS is as many as 30,000 in the U.S, also 5,000 new cases are being diagnosed each year. According to estimates, more than five of every 100,000 deaths in people aged 20 or above are attributed to Amyotrophic Lateral Sclerosis (ALS). The prevalence incidence of ALS is about equal to multiple sclerosis and five times higher than Huntington’s disease. Up to now only four drugs have FDA-approval to treat ALS; Riluzole, Radicava, Nuedexta and Tiglutik. The one and only medicine that has been noticed in the American Academy of Neurology (AAN) guideline regarding management and care of the patient with amyotrophic lateral sclerosis (ALS), is Riluzole. The only medication that has shown efficacy in extending life in Amyotrophic Lateral Sclerosis (ALS), is Riluzole. Riluzole’s mechanism of action is not known. Pharmacologic properties include inactivation of voltage-dependent sodium channels, inhibitory effect on glutamate release and ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Hence, one of Parsian’s fields of activity is research and development in ALS to manufacture active pharmaceutical ingredients (API) of ALS medicines with the highest global standards to help patients who are battling with ALS to have fewer concerns by the latest guidelines and with the lowest adverse effects.